ENOV — Enovis Corporation stock price, charts and financials

QT59Enovis Corporation

Enovis Corporation (NYSE: ENOV) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
24.89
-1.72-6.46%
ENOVQT59Enovis Corporation·NYSE
24.89-6.46%
News
Down 6.5% — Enovis Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-20.02Insider Own9.07%Shs Outstand57.56MPerf Week-8.71%
Market Cap1.53BForward P/E6.53EPS next Y4.07Insider Trans0.20%Shs Float56.59MPerf Month5.51%
Enterprise Value2.89BPEG0.02EPS next Q-Inst Own-Short Float14.74%Perf Quarter-2.35%
Income-1.10BP/S0.67EPS this Y118.18%Inst Trans-Short Ratio7.16Perf Half Y22.12%
Sales2.30BP/B1.04EPS next Y11.90%ROA-29.25%Short Interest8.34MPerf YTD-0.11%
Book/sh-P/C5.67EPS next 5Y10.90%ROE-68.17%52W High32.06 -22.37%Perf Year3.30%
Cash/sh-P/FCF24.06EPS past 3/5Y-ROIC2.95%52W Low17.90 39.03%Perf 3Y-57.63%
Dividend Est.-EV/EBITDA-Sales past 3/5Y12.88% 14.93%Gross Margin57.43%Volatility6.44% 5.12%Perf 5Y-66.30%
Dividend TTM-EV/Sales1.26EPS Y/Y TTM-34.09%Oper. Margin4.14%ATR (14)1.72Perf 10Y-47.05%
Dividend Ex-Date-Quick Ratio1.00Sales Y/Y TTM8.11%Profit Margin-47.97%RSI (14)48.32Recom2.23
Dividend Gr. 3/5Y-Current Ratio1.98EPS Q/Q9.88%SMA20-4.46%Beta1.10Target Price41.25
Payout0.00%Debt/Eq0.93Sales Q/Q5.37%SMA507.96%Rel Volume1.68Prev Close26.60
Employees7,802LT Debt/Eq0.88EarningsNov 05SMA2004.64%Avg Volume1.22MPrice24.89
IPO DateMay 08, 2008Option/ShortYes / YesEPS/Sales Surpr.9.54% 2.99%Net Debt/EBITDA-1.89Volume2,058,435Change-6.46%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedBMO Capital$29$30
Jul-28-26ReiteratedUBSBuy$50$51
Jul-08-26InitiatedBMO CapitalOutperform$29
Jul-06-26ReiteratedEvercore ISI GroupOutperform$36$32
May-08-26ReiteratedEvercore ISI GroupOutperform$40$36
Feb-26-26ReiteratedNeedhamBuy$65$52
Jan-06-26InitiatedBTIGBuy$41
Jan-05-26ReiteratedEvercore ISIOutperform$44$40
Jan-05-26ReiteratedUBSBuy$50
Dec-17-25ReiteratedCanaccord GenuityBuy$50
Latest News
Aug-08-26
Aug-08-2602:04AM
Aug-06-26
Jul-21-26
Jul-17-26
Jul-13-26
Jul-10-26
Jul-06-26
Jul-03-26
Company

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,2972,2482,108
Cost of Goods Sold Incl. D&A978903927
Gross Profit1,3191,3451,181
Selling, General and Administrative Excl. Other1,0541,070939
Research and Development12512091
Other Operating Expense45174926
Operating Income94-19-776
Interest Expense563557
Unusual Expense
Non-Operating Income (Expense)-1,107-1,10610
Net Income Before Taxes-1,069-1,159-823
Income Taxes31224
Consolidated Net Income-1,102-1,184-825
Net Income From Continuing Operations-1,099-1,182-827
Net Income-1,102-1,184-825
EPS (Recurring)-19.40-20.86-14.93
EPS (Basic, Before Extraordinaries)-19.40-20.86-14.93
EPS (Diluted)-19.40-20.86-14.93
EBITDA-717-830-481
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio0.630.681.14
Gross Margin57.4259.8356.02
Operating Margin4.09-0.85-36.81
Net Margin-47.98-52.67-39.14
Shares Outstanding585755
Market Capitalization1,4431,5182,413
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$38.32$33.16$27.99$22.82$17.66 Close Price0.00K115.95K231.89K347.84K463.79KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Engert OliverChief Administrative OfficerJun 15 '26Buy20.921,00020,92053,640Jun 16
Engert OliverChief Administrative OfficerJun 11 '26Buy21.621,20025,94851,840Jun 15
Engert OliverChief Administrative OfficerJun 10 '26Buy23.001,00023,00050,640Jun 11
Engert OliverChief Administrative OfficerJun 01 '26Buy22.221,00022,22049,640Jun 03
Engert OliverChief Administrative OfficerMar 13 '26Buy23.741,00023,74048,640Mar 16
Engert OliverChief Administrative OfficerMar 10 '26Buy23.931,00023,93047,640Mar 12
Engert OliverChief Administrative OfficerMar 09 '26Buy23.391,00023,39046,640Mar 10
Engert OliverChief Administrative OfficerMar 06 '26Buy24.4175018,31045,640Mar 10
Engert OliverChief Administrative OfficerMar 04 '26Buy25.102506,27544,890Mar 05
Engert OliverChief Administrative OfficerMar 03 '26Buy24.771,00024,77044,640Mar 05
Engert OliverChief Administrative OfficerFeb 27 '26Buy25.501,00025,50043,640Mar 03
PRYOR DANIEL Aother: Former EVP, Strategy & Bus DevDec 09 '25Sale27.211,66545,2980Dec 11
KLECKNER JOHNPrincipal Accounting OfficerNov 25 '25Buy30.322,46874,83012,302Nov 28
McDonald DamienChief Executive OfficerSep 11 '25Buy30.976,457199,973102,753Sep 11
Tandy Bradley JSVP and Chief Legal OfficerAug 22 '25Buy31.413,200100,51243,515Aug 25
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.